Table 1 Patient and treatment related parameters
Gender | |
Male | 68 (88%) |
Female | 9 (12%) |
Mean age (years, range) | 67 (35–87) |
Mean gross primary tumor volume (pGTV, ml, range) | 9.5 (0.2–88.7) |
Planning target volume (PTV, ml, range)) | 76.2 (18–283) |
T-stage | |
T1 | 17 (22%) |
T2 | 24 (31%) |
T3 | 15 (20%) |
T4 | 13 (17%) |
Recurrence | 8 (10%) |
N-stage | |
N0 | 63 (79%) |
N1 | 4 (5%) |
N2a | 0 |
N2b | 5 (8%) |
N2c | 5 (8%) |
N3 | 0 |
Concomitant systemic therapy | 39 (51%) |
Cisplatin | 26 (34%) |
Cetuximab | 14 (18%) |
Both (sequentially n = 2, simultaneously n = 1) | 3 (4%) |
RT prescription dose (total/single) | |
61.6/2.2 Gy | 1 (1%) |
63/2.25 Gy | 2 (3%) |
69.6/2.11 Gy | 7 (9%) |
66/2 Gy (6 f/week) | 10 (13%) |
68/2 Gy (6 f/week) | 25 (32%) |
70/2 Gy | 32 (42%) |